Within oncology, we are applying our ImmTAC® platform to overcome the limitations of current anti-cancer therapies to deliver:
- Potent and specific re-direction of a patient’s own T cells to kill the target cancer cells.
- Access to a pool of antigenic targets that is up to nine-fold greater than traditional antibody-based therapies.
This unique and potent mechanism of action provided by ImmTAC® molecules gives the potential to tackle diverse tumour types, including solid tumours that are characteristically immune excluded, or "cold" and thus resistant to the majority of existing immunotherapies that target activation of pre-existing immune cells. ImmTAC® molecules have the potential to convert "cold" tumours to "hot" through their T cell redirecting activity.
Beyond IMCgp100, we are continuing to apply our ImmTAC® technology to target a diverse range of cancer indications.
Uveal melanoma is an aggressive form of melanoma that arises from melanocytes in the uveal tract of the eye. Survival in uveal melanoma has remained largely unchanged since the early 1970s with the greatest burden in metastatic disease. Currently, there is no proven standard of care for metastatic uveal melanoma, meanwhile various therapies, including checkpoint inhibitors, are used without definitive evidence of benefit in this patient population.
IMCgp100 is designed to specifically target the melanoma-associated antigen gp100 and engages T cells to direct a potent and specific response against the cancer cell.